INVESTIGATIONAL MOLECULE NAME THERAPEUTIC AREA MODALITY PHASE INDICATION
AIMOVIG® Neuroscience Pediatric Migraine Monoclonal Antibody (erenumab-aooe)
DESCRIPTION Aimovig is a monoclonal antibody that inhibits the calcitonin gene-related peptide receptor (CGRP-R). It is being investigated for prevention of chronic and episodic migraine in pediatric patients.
EVENITY® Bone Male Osteoporosis Monoclonal Antibody (romosozumab-aqqg)
DESCRIPTION EVENITY is a monoclonal antibody that inhibits the action of sclerostin. It is being investigated for the treatment of male osteoporosis.
ADDITIONAL INFORMATION EVENITY is being developed in collaboration with UCB.
KYPROLIS® Hematology/Oncology Multiple Myeloma Small Molecule (carfilzomib)
DESCRIPTION KYPROLIS is a small molecule proteasome inhibitor (PI). It is being investigated for weekly dosing in combinations with lenalidomide and dexamethasone for the treatment of relapsed multiple myeloma.
Hematology/Oncology Pediatric Acute Lymphoblastic Leukemia Small Molecule
DESCRIPTION KYPROLIS is a small molecule proteasome inhibitor (PI). It is being investigated for the treatment of acute lymphoblastic leukemia (ALL) in pediatric patients.
*Modalities in use across pipeline and marketed products. Modality refers to the structural template of a therapeutic agent.
This pipeline presents a selection of the Company’s product candidates and is designed to demonstrate the range of the Company’s commitment to patients in pursuing therapies to treat serious illnesses. We present a selection of these product candidates in our periodic reports based on their importance to the Company and our Annual Report on Form 10-K also includes an annual summary of activity for those Phase 3 product candidates selected for inclusion in our periodic filings. Unless otherwise noted, we are providing this information as of August 3, 2021 and expressly disclaim any duty to update any of the provided information. Amgen's product pipeline will change over time as molecules move through the drug development process, including progressing through clinical phases to licensure and market, returning to strategic partners, being outlicensed, or failing in clinical trials to demonstrate efficacy, safety or to deliver a commercially viable product, due to the nature of the development process. This description contains forward-looking statements that involve significant risks and uncertainties, including those discussed in Amgen's most recent Form 10-K and in Amgen's periodic reports on Form 10-Q and Form 8-K, and actual results may vary materially. Amgen is providing this information as of the date above and does not undertake any obligation to update any forward-looking statements contained in this table as a result of new information, future events or otherwise.
© 2021 Amgen Inc. All rights reserved. PAGE 1
INVESTIGATIONAL MOLECULE NAME THERAPEUTIC AREA MODALITY PHASE INDICATION
LUMAKRAS™ (sotorasib) Hematology/Oncology Non-Small Cell Lung Cancer Small Molecule
DESCRIPTION LUMAKRAS is a KRASG12C small molecule inhibitor under investigation for the treatment of advanced non-small cell lung cancer.
ADDITIONAL INFORMATION LUMAKRAS received accelerated approval by the FDA in May 2021 for the treatment of patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC), as determined by an FDA-approved test, following at least one prior systemic therapy. Marketing applications are also under review with additional agencies, some under FDA’s Project Orbis initiative.
Hematology/Oncology Advanced Colorectal Cancer Small Molecule
DESCRIPTION LUMAKRAS is a KRASG12C small molecule inhibitor under investigation for the treatment of advanced colorectal cancer.
ADDITIONAL INFORMATION LUMAKRAS received accelerated approval by the FDA in May 2021 for the treatment of patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC), as determined by an FDA-approved test, following at least one prior systemic therapy. Marketing applications are also under review with additional agencies, some under FDA’s Project Orbis initiative.
Hematology/Oncology Other Tumors Small Molecule
DESCRIPTION LUMAKRAS is a KRASG12C small molecule inhibitor under investigation for the treatment of advanced solid tumors other than non- small cell lung cancer or advanced colorectal cancer.
ADDITIONAL INFORMATION LUMAKRAS received accelerated approval by the FDA in May 2021 for the treatment of patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC), as determined by an FDA-approved test, following at least one prior systemic therapy. Marketing applications are also under review with additional agencies, some under FDA’s Project Orbis initiative.
® NPLATE Hematology/Oncology Chemotherapy-Induced Peptibody (romiplostim) Thrombocytopenia
DESCRIPTION Nplate is a thrombopoietin receptor agonist (TPO-RA). It is being investigated for the treatment of chemotherapy-induced thrombocytopenia (CIT).
*Modalities in use across pipeline and marketed products. Modality refers to the structural template of a therapeutic agent.
This pipeline presents a selection of the Company’s product candidates and is designed to demonstrate the range of the Company’s commitment to patients in pursuing therapies to treat serious illnesses. We present a selection of these product candidates in our periodic reports based on their importance to the Company and our Annual Report on Form 10-K also includes an annual summary of activity for those Phase 3 product candidates selected for inclusion in our periodic filings. Unless otherwise noted, we are providing this information as of August 3, 2021 and expressly disclaim any duty to update any of the provided information. Amgen's product pipeline will change over time as molecules move through the drug development process, including progressing through clinical phases to licensure and market, returning to strategic partners, being outlicensed, or failing in clinical trials to demonstrate efficacy, safety or to deliver a commercially viable product, due to the nature of the development process. This description contains forward-looking statements that involve significant risks and uncertainties, including those discussed in Amgen's most recent Form 10-K and in Amgen's periodic reports on Form 10-Q and Form 8-K, and actual results may vary materially. Amgen is providing this information as of the date above and does not undertake any obligation to update any forward-looking statements contained in this table as a result of new information, future events or otherwise.
© 2021 Amgen Inc. All rights reserved. PAGE 2
INVESTIGATIONAL MOLECULE NAME THERAPEUTIC AREA MODALITY PHASE INDICATION
OTEZLA® (apremilast) Inflammation Pediatric Plaque Psoriasis Small Molecule
DESCRIPTION Otezla is a small molecule that inhibits phosphodiesterase 4 (PDE4). It is being investigated for the treatment of moderate to severe plaque psoriasis in pediatric patients.
Inflammation Mild to Moderate Plaque Psoriasis Small Molecule
DESCRIPTION Otezla is a small molecule that inhibits phosphodiesterase 4 (PDE4). It is being investigated for the treatment of mild to moderate plaque psoriasis.
Inflammation Genital Psoriasis Small Molecule
DESCRIPTION Otezla is a small molecule that inhibits phosphodiesterase 4 (PDE4). It is being investigated for the treatment of moderate to severe genital psoriasis.
Inflammation Juvenile Psoriatic Arthritis Small Molecule
DESCRIPTION Otezla is a small molecule that inhibits phosphodiesterase 4 (PDE4). It is being investigated for the treatment of juvenile psoriatic arthritis in pediatric patients.
Inflammation Pediatric Behcet’s Disease Small Molecule
DESCRIPTION Otezla is a small molecule that inhibits phosphodiesterase 4 (PDE4). It is being investigated for the treatment of Behcet’s disease in pediatric patients.
Inflammation COVID-19 Small Molecule
DESCRIPTION Otezla is a small molecule that inhibits phosphodiesterase 4 (PDE4). It is being investigated as a potential immunomodulatory treatment in adult patients hospitalized for COVID-19 in partnership with some of the members of the COVID R&D Alliance.
Inflammation Palmoplantar Pustulosis Small Molecule
DESCRIPTION Otezla is a small molecule that inhibits phosphodiesterase 4 (PDE4). It is being investigated for the treatment of palmoplantar pustulosis.
*Modalities in use across pipeline and marketed products. Modality refers to the structural template of a therapeutic agent.
This pipeline presents a selection of the Company’s product candidates and is designed to demonstrate the range of the Company’s commitment to patients in pursuing therapies to treat serious illnesses. We present a selection of these product candidates in our periodic reports based on their importance to the Company and our Annual Report on Form 10-K also includes an annual summary of activity for those Phase 3 product candidates selected for inclusion in our periodic filings. Unless otherwise noted, we are providing this information as of August 3, 2021 and expressly disclaim any duty to update any of the provided information. Amgen's product pipeline will change over time as molecules move through the drug development process, including progressing through clinical phases to licensure and market, returning to strategic partners, being outlicensed, or failing in clinical trials to demonstrate efficacy, safety or to deliver a commercially viable product, due to the nature of the development process. This description contains forward-looking statements that involve significant risks and uncertainties, including those discussed in Amgen's most recent Form 10-K and in Amgen's periodic reports on Form 10-Q and Form 8-K, and actual results may vary materially. Amgen is providing this information as of the date above and does not undertake any obligation to update any forward-looking statements contained in this table as a result of new information, future events or otherwise.
© 2021 Amgen Inc. All rights reserved. PAGE 3
INVESTIGATIONAL MOLECULE NAME THERAPEUTIC AREA MODALITY PHASE INDICATION
® PARSABIV Nephrology Pediatric Secondary Peptide (etelcalcetide) Hyperparathyroidism
DESCRIPTION Parsabiv is a calcium-sensing receptor agonist. It is being investigated for the treatment of secondary hyperparathyroidism (HPT) in pediatric patients with chronic kidney disease (CKD) receiving hemodialysis.
® PROLIA Bone Pediatric Glucocorticoid-Induced Monoclonal Antibody (denosumab) Osteoporosis
DESCRIPTION Prolia is a monoclonal antibody that inhibits RANK ligand. It is being investigated for the treatment of glucocorticoid-induced osteoporosis (GIOP) in pediatric patients.
Bone Pediatric Osteogensis Imperfecta Monoclonal Antibody
DESCRIPTION Prolia is a monoclonal antibody that inhibits RANK ligand. It is being investigated for the treatment of osteogenesis imperfecta in pediatric patients.
REPATHA® Cardiometabolic Hypercholesterolemia Monoclonal Antibody (evolocumab)
DESCRIPTION Repatha is a monoclonal antibody that inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9). It is being investigated for the treatment of patients with high-risk cardiovascular disease without prior heart attack or stroke.
Pediatric Familial Cardiometabolic Monoclonal Antibody Hypercholesterolemia
DESCRIPTION Repatha is a monoclonal antibody that inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9). It is being investigated for the treatment of familial hypercholesterolemia in pediatric patients.
*Modalities in use across pipeline and marketed products. Modality refers to the structural template of a therapeutic agent.
This pipeline presents a selection of the Company’s product candidates and is designed to demonstrate the range of the Company’s commitment to patients in pursuing therapies to treat serious illnesses. We present a selection of these product candidates in our periodic reports based on their importance to the Company and our Annual Report on Form 10-K also includes an annual summary of activity for those Phase 3 product candidates selected for inclusion in our periodic filings. Unless otherwise noted, we are providing this information as of August 3, 2021 and expressly disclaim any duty to update any of the provided information. Amgen's product pipeline will change over time as molecules move through the drug development process, including progressing through clinical phases to licensure and market, returning to strategic partners, being outlicensed, or failing in clinical trials to demonstrate efficacy, safety or to deliver a commercially viable product, due to the nature of the development process. This description contains forward-looking statements that involve significant risks and uncertainties, including those discussed in Amgen's most recent Form 10-K and in Amgen's periodic reports on Form 10-Q and Form 8-K, and actual results may vary materially. Amgen is providing this information as of the date above and does not undertake any obligation to update any forward-looking statements contained in this table as a result of new information, future events or otherwise.
© 2021 Amgen Inc. All rights reserved. PAGE 4
INVESTIGATIONAL MOLECULE NAME THERAPEUTIC AREA MODALITY PHASE INDICATION
TEZEPELUMAB Inflammation Severe Asthma Monoclonal Antibody
DESCRIPTION Tezepelumab is a monoclonal antibody that inhibits the action of thymic stromal lymphopoietin (TSLP). It is being investigated for the treatment of severe asthma.
ADDITIONAL INFORMATION In September 2018, we announced that the FDA granted Breakthrough Therapy Designation for tezepelumab in patients with severe asthma without an eosinophilic phenotype.
Tezepelumab is being developed in collaboration with AstraZeneca plc.
Inflammation Chronic Rhinosinusitis with Nasal Polyps Monoclonal Antibody
DESCRIPTION Tezepelumab is a monoclonal antibody that inhibits the action of the thymic stromal lymphopoietin (TSLP). It is being investigated for the treatment of chronic rhinosinusitis with nasal polyps (CRSwNP).
ADDITIONAL INFORMATION Tezepelumab is being developed in collaboration with AstraZeneca plc.
Inflammation Chronic Obstructive Pulmonary Monoclonal Antibody Disease
DESCRIPTION Tezepelumab is a monoclonal antibody that inhibits the action of the thymic stromal lymphopoietin (TSLP). It is being investigated for the treatment of chronic obstructive pulmonary disease (COPD).
ADDITIONAL INFORMATION Tezepelumab is being developed in collaboration with AstraZeneca plc.
Inflammation Chronic Spontaneous Urticaria Monoclonal Antibody
DESCRIPTION Tezepelumab is a monoclonal antibody that inhibits the action of the thymic stromal lymphopoietin (TSLP). It is being investigated for the treatment of chronic spontaneous urticaria (CSU).
ADDITIONAL INFORMATION Tezepelumab is being developed in collaboration with AstraZeneca plc.
*Modalities in use across pipeline and marketed products. Modality refers to the structural template of a therapeutic agent.
This pipeline presents a selection of the Company’s product candidates and is designed to demonstrate the range of the Company’s commitment to patients in pursuing therapies to treat serious illnesses. We present a selection of these product candidates in our periodic reports based on their importance to the Company and our Annual Report on Form 10-K also includes an annual summary of activity for those Phase 3 product candidates selected for inclusion in our periodic filings. Unless otherwise noted, we are providing this information as of August 3, 2021 and expressly disclaim any duty to update any of the provided information. Amgen's product pipeline will change over time as molecules move through the drug development process, including progressing through clinical phases to licensure and market, returning to strategic partners, being outlicensed, or failing in clinical trials to demonstrate efficacy, safety or to deliver a commercially viable product, due to the nature of the development process. This description contains forward-looking statements that involve significant risks and uncertainties, including those discussed in Amgen's most recent Form 10-K and in Amgen's periodic reports on Form 10-Q and Form 8-K, and actual results may vary materially. Amgen is providing this information as of the date above and does not undertake any obligation to update any forward-looking statements contained in this table as a result of new information, future events or otherwise.
© 2021 Amgen Inc. All rights reserved. PAGE 5
INVESTIGATIONAL MOLECULE NAME THERAPEUTIC AREA MODALITY PHASE INDICATION
ABP 654 Inflammation Biosimilar candidate to STELARA Monoclonal Antibody (STELARA® biosimilar)
DESCRIPTION ABP 654 (ustekinumab), a biosimilar candidate to STELARA, is a monoclonal antibody that inhibits IL-12 and IL-23.
ADDITIONAL INFORMATION STELARA is a registered trademark of Johnson & Johnson.
ABP 938 (EYLEA® biosimilar) Inflammation Biosimilar candidate to EYLEA Fusion Protein
DESCRIPTION ABP 938 (aflibercept), a biosimilar candidate to EYLEA, is a vascular endothelial growth factor receptor (VEGFR) Fc fusion protein.
ADDITIONAL INFORMATION EYLEA is a registered trademark of Regeneron Pharmaceuticals, Inc.
ABP 959 Hematology/Oncology Biosimilar candidate to Soliris Monoclonal Antibody (Soliris® biosimilar)
DESCRIPTION ABP 959 (eculizumab), a biosimilar candidate to Soliris, is a monoclonal antibody that specifically binds to the complement protein C5.
ADDITIONAL INFORMATION Soliris is a registered trademark of Alexion Pharmaceuticals Inc.
BEMARITUZUMAB Gastric Cancer and Gastroesophageal Hematology/Oncology Monoclonal Antibody Junction (GEJ) Adenocarcinoma
DESCRIPTION Bemarituzumab is a monoclonal antibody that inhibits fibroblast growth factor receptor 2b (FGFR2b). It is being investigated for the treatment of advanced Gastric Cancer and Gastroesophageal Junction (GEJ) Adenocarcinoma.
ADDITIONAL INFORMATION In April 2021, Amgen announced that the FDA granted Breakthrough Therapy Designation for bemarituzumab.
*Modalities in use across pipeline and marketed products. Modality refers to the structural template of a therapeutic agent.
This pipeline presents a selection of the Company’s product candidates and is designed to demonstrate the range of the Company’s commitment to patients in pursuing therapies to treat serious illnesses. We present a selection of these product candidates in our periodic reports based on their importance to the Company and our Annual Report on Form 10-K also includes an annual summary of activity for those Phase 3 product candidates selected for inclusion in our periodic filings. Unless otherwise noted, we are providing this information as of August 3, 2021 and expressly disclaim any duty to update any of the provided information. Amgen's product pipeline will change over time as molecules move through the drug development process, including progressing through clinical phases to licensure and market, returning to strategic partners, being outlicensed, or failing in clinical trials to demonstrate efficacy, safety or to deliver a commercially viable product, due to the nature of the development process. This description contains forward-looking statements that involve significant risks and uncertainties, including those discussed in Amgen's most recent Form 10-K and in Amgen's periodic reports on Form 10-Q and Form 8-K, and actual results may vary materially. Amgen is providing this information as of the date above and does not undertake any obligation to update any forward-looking statements contained in this table as a result of new information, future events or otherwise.
© 2021 Amgen Inc. All rights reserved. PAGE 6
INVESTIGATIONAL MOLECULE NAME THERAPEUTIC AREA MODALITY PHASE INDICATION
EFAVALEUKIN ALFA Inflammation Systemic Lupus Erythematosus Fusion Protein (formerly AMG 592)
DESCRIPTION Efavaleukin alfa (formerly AMG 592) is an IL-2 mutein Fc fusion protein. It is being investigated for the treatment of systemic lupus erythematosus.
Inflammation Graft Versus Host Diseases Fusion Protein
DESCRIPTION Efavaleukin alfa (formerly AMG 592) is an IL-2 mutein Fc fusion protein. It is being investigated for the treatment of graft versus host disease.
OLPASIRAN Cardiometabolic Cardiovascular Disease siRNA (formerly AMG 890)
DESCRIPTION Olpasiran (formerly AMG 890) is a small interfering RNA (siRNA) that lowers lipoprotein(a), also known as Lp(a). It is being investigated for the treatment of atherosclerotic cardiovascular disease.
ROZIBAFUSP ALFA Inflammation Systemic Lupus Erythematosus Antibody-Peptide Conjugate (formerly AMG 570)
DESCRIPTION Rozibafusp alfa (formerly AMG 570) is a novel antibody-peptide conjugate that simultaneously blocks ICOSL and BAFF activity. It is being investigated for the treatment of systemic lupus erythematosus.
AMG 451 / KHK4083 Inflammation Atopic Dermatitis Monoclonal Antibody
DESCRIPTION AMG 451 (KHK4083) is a monoclonal antibody that inhibits OX-40. It is being investigated for the treatment of moderate-to-severe atopic dermatitis.
ADDITIONAL INFORMATION AMG 451 (KHK4083) is being developed in collaboration with Kyowa Kirin Co., Ltd.
*Modalities in use across pipeline and marketed products. Modality refers to the structural template of a therapeutic agent.
This pipeline presents a selection of the Company’s product candidates and is designed to demonstrate the range of the Company’s commitment to patients in pursuing therapies to treat serious illnesses. We present a selection of these product candidates in our periodic reports based on their importance to the Company and our Annual Report on Form 10-K also includes an annual summary of activity for those Phase 3 product candidates selected for inclusion in our periodic filings. Unless otherwise noted, we are providing this information as of August 3, 2021 and expressly disclaim any duty to update any of the provided information. Amgen's product pipeline will change over time as molecules move through the drug development process, including progressing through clinical phases to licensure and market, returning to strategic partners, being outlicensed, or failing in clinical trials to demonstrate efficacy, safety or to deliver a commercially viable product, due to the nature of the development process. This description contains forward-looking statements that involve significant risks and uncertainties, including those discussed in Amgen's most recent Form 10-K and in Amgen's periodic reports on Form 10-Q and Form 8-K, and actual results may vary materially. Amgen is providing this information as of the date above and does not undertake any obligation to update any forward-looking statements contained in this table as a result of new information, future events or otherwise.
© 2021 Amgen Inc. All rights reserved. PAGE 7
INVESTIGATIONAL MOLECULE NAME THERAPEUTIC AREA MODALITY PHASE INDICATION
AMG 714 / PRV-015 Inflammation Celiac Disease Monoclonal Antibody
DESCRIPTION AMG 714 is a monoclonal antibody that inhibits the action of Interleukin-15 (IL-15). It is being investigated for the treatment of celiac disease.
ADDITIONAL INFORMATION AMG 714 (also known as PRV-015) is being developed in collaboration with Provention Bio.
ACAPATAMAB Hematology/Oncology Prostate Cancer BiTE® Molecule (formerly AMG 160)
DESCRIPTION Acapatamab (formerly AMG 160) is a half-life extended (HLE) anti- prostate-specific membrane antigen (PSMA) x anti-CD3 bispecific T cell engager (BiTE) molecule. It is being investigated for the treatment of prostate cancer.
® Hematology/Oncology Non-Small Cell Lung Cancer BiTE Molecule
DESCRIPTION Acapatamab (formerly AMG 160) is a half-life extended (HLE) anti- prostate-specific membrane antigen (PSMA) x anti-CD3 bispecific T cell engager (BiTE) molecule. It is being investigated for the treatment of non-small cell lung cancer (NSCLC).
PAVURUTAMAB ® (formerly AMG 701) Hematology/Oncology Multiple Myeloma BiTE Molecule
DESCRIPTION Pavurutamab (formerly AMG 701) is a half-life extended (HLE) anti-B-cell maturation antigen (BCMA) x anti-CD3 bispecific T cell engager (BiTE) molecule. It is being investigated for the treatment of multiple myeloma.
TARLATAMAB (formerly AMG 757) Hematology/Oncology Small Cell Lung Cancer BiTE® Molecule
DESCRIPTION Tarlatamab (formerly AMG 757) is a half-life extended (HLE) anti- delta-like ligand 3 (DLL3) x anti-CD3 bispecific T cell engager (BiTE) molecule. It is being investigated for the treatment of small cell lung cancer.
Hematology/Oncology Neuroendocrine Prostate Cancer BiTE® Molecule
DESCRIPTION Tarlatamab (formerly AMG 757) is a half-life extended (HLE) anti- delta-like ligand 3 (DLL3) x anti-CD3 bispecific T cell engager (BiTE) molecule. It is being investigated for the treatment of neuroendocrine prostate cancer.
*Modalities in use across pipeline and marketed products. Modality refers to the structural template of a therapeutic agent.
This pipeline presents a selection of the Company’s product candidates and is designed to demonstrate the range of the Company’s commitment to patients in pursuing therapies to treat serious illnesses. We present a selection of these product candidates in our periodic reports based on their importance to the Company and our Annual Report on Form 10-K also includes an annual summary of activity for those Phase 3 product candidates selected for inclusion in our periodic filings. Unless otherwise noted, we are providing this information as of August 3, 2021 and expressly disclaim any duty to update any of the provided information. Amgen's product pipeline will change over time as molecules move through the drug development process, including progressing through clinical phases to licensure and market, returning to strategic partners, being outlicensed, or failing in clinical trials to demonstrate efficacy, safety or to deliver a commercially viable product, due to the nature of the development process. This description contains forward-looking statements that involve significant risks and uncertainties, including those discussed in Amgen's most recent Form 10-K and in Amgen's periodic reports on Form 10-Q and Form 8-K, and actual results may vary materially. Amgen is providing this information as of the date above and does not undertake any obligation to update any forward-looking statements contained in this table as a result of new information, future events or otherwise.
© 2021 Amgen Inc. All rights reserved. PAGE 8
INVESTIGATIONAL MOLECULE NAME THERAPEUTIC AREA MODALITY PHASE INDICATION
AMG 119 Hematology/Oncology Small Cell Lung Cancer CAR-T
DESCRIPTION AMG 119 is a delta-like ligand 3 (DLL3) chimeric antigen receptor T cell (CAR T) cellular therapy. It is being investigated for the treatment of small cell lung cancer.
AMG 133 Cardiometabolic Obesity Antibody-Peptide Conjugate
DESCRIPTION AMG 133 is a gastric inhibitory polypeptide receptor (GIPR) antagonist and glucagon-like peptide 1 (GLP-1) receptor agonist. It is being investigated for the treatment of obesity.
AMG 171 Cardiometabolic Obesity Fusion Protein
DESCRIPTION AMG 171 is a Growth Differential Factor 15 (GDF15) analog. It is being investigated for the treatment of obesity.
AMG 176 Hematology/Oncology Hematology Small Molecule
DESCRIPTION AMG 176 is a small molecule inhibitor of myeloid cell leukemia 1 (MCL-1). It is being investigated for the treatment of hematologic malignancies.
AMG 199 Hematology/Oncology Metastatic Gastric and BiTE® Molecule Gastroesophageal Junction Cancer
DESCRIPTION AMG 199 is a half-life extended (HLE) anti-MUC17 x anti-CD3 bispecific T cell engager (BiTE) molecule. It is being investigated for the treatment of gastric and gastroesophageal junction cancer.
AMG 256 Hematology/Oncology Solid Tumors Bifunctional Fusion Protein
DESCRIPTION AMG 256 (anti-PD-1 x IL21 mutein) is a targeted IL-21 receptor agonist designed to selectively turn on the Interleukin 21 (IL-21) pathway in programmed cell death-1 (PD-1) positive cells. It is being investigated for the treatment of solid tumors.
*Modalities in use across pipeline and marketed products. Modality refers to the structural template of a therapeutic agent.
This pipeline presents a selection of the Company’s product candidates and is designed to demonstrate the range of the Company’s commitment to patients in pursuing therapies to treat serious illnesses. We present a selection of these product candidates in our periodic reports based on their importance to the Company and our Annual Report on Form 10-K also includes an annual summary of activity for those Phase 3 product candidates selected for inclusion in our periodic filings. Unless otherwise noted, we are providing this information as of August 3, 2021 and expressly disclaim any duty to update any of the provided information. Amgen's product pipeline will change over time as molecules move through the drug development process, including progressing through clinical phases to licensure and market, returning to strategic partners, being outlicensed, or failing in clinical trials to demonstrate efficacy, safety or to deliver a commercially viable product, due to the nature of the development process. This description contains forward-looking statements that involve significant risks and uncertainties, including those discussed in Amgen's most recent Form 10-K and in Amgen's periodic reports on Form 10-Q and Form 8-K, and actual results may vary materially. Amgen is providing this information as of the date above and does not undertake any obligation to update any forward-looking statements contained in this table as a result of new information, future events or otherwise.
© 2021 Amgen Inc. All rights reserved. PAGE 9
INVESTIGATIONAL MOLECULE NAME THERAPEUTIC AREA MODALITY PHASE INDICATION
AMG 330 ® Hematology/Oncology Acute Myeloid Leukemia BiTE Molecule
DESCRIPTION AMG 330 is an anti-CD33 x anti-CD3 bispecific T cell engager (BiTE) molecule. It is being investigated for the treatment of acute myeloid leukemia.
AMG 397 Hematology/Oncology Hematology Small Molecule
DESCRIPTION AMG 397 is a small molecule inhibitor of myeloid cell leukemia 1 (MCL-1). It is being investigated for the treatment of hematologic malignancies.
AMG 404 Hematology/Oncology Solid Tumors Monoclonal Antibody
DESCRIPTION AMG 404 is an anti-programmed cell death-1 (PD-1) monoclonal antibody being investigated as a treatment for patients with solid tumors. It is being developed for use in combination with other Amgen oncology portfolio molecules.
AMG 427 Hematology/Oncology Acute Myeloid Leukemia BiTE® Molecule
DESCRIPTION AMG 427 is a half-life extended (HLE) anti-fms-like tyrosine kinase 3 (FLT3) x anti-CD3 bispecific T cell engager (BiTE) molecule. It is being investigated for the treatment of acute myeloid leukemia (AML).
AMG 506 ® Hematology/Oncology Solid Tumors DARPin protein
DESCRIPTION AMG 506 is a multi-specific FAP x 4-1BB-targeting DARPin biologic under investigation as a treatment for solid tumors. It is being developed for use in combination with other Amgen oncology portfolio molecules.
ADDITIONAL INFORMATION AMG 506 (also known as MP0310) is being developed in collaboration with Molecular Partners AG. DARPin is a registered trademark owned by Molecular Partners AG.
*Modalities in use across pipeline and marketed products. Modality refers to the structural template of a therapeutic agent.
This pipeline presents a selection of the Company’s product candidates and is designed to demonstrate the range of the Company’s commitment to patients in pursuing therapies to treat serious illnesses. We present a selection of these product candidates in our periodic reports based on their importance to the Company and our Annual Report on Form 10-K also includes an annual summary of activity for those Phase 3 product candidates selected for inclusion in our periodic filings. Unless otherwise noted, we are providing this information as of August 3, 2021 and expressly disclaim any duty to update any of the provided information. Amgen's product pipeline will change over time as molecules move through the drug development process, including progressing through clinical phases to licensure and market, returning to strategic partners, being outlicensed, or failing in clinical trials to demonstrate efficacy, safety or to deliver a commercially viable product, due to the nature of the development process. This description contains forward-looking statements that involve significant risks and uncertainties, including those discussed in Amgen's most recent Form 10-K and in Amgen's periodic reports on Form 10-Q and Form 8-K, and actual results may vary materially. Amgen is providing this information as of the date above and does not undertake any obligation to update any forward-looking statements contained in this table as a result of new information, future events or otherwise.
© 2021 Amgen Inc. All rights reserved. PAGE 10
INVESTIGATIONAL MOLECULE NAME THERAPEUTIC AREA MODALITY PHASE INDICATION
AMG 509 ® Hematology/Oncology Prostate Cancer XmAb Antibody
DESCRIPTION AMG 509 (STEAP1 XmAb antibody) is a bivalent T cell engager and is designed using XmAb 2+1 technology. It is being investigated for the treatment of prostate cancer.
ADDITIONAL INFORMATION XmAb is a registered trademark of Xencor, Inc.
AMG 609 Metabolic Disorders Nonalcoholic Steatohepatitis siRNA Small Molecule
DESCRIPTION AMG 609 is a small interfering RNA (siRNA) that selectively targets a variant allele of patatin like phospholipase domain containing 3, also known as PNPLA3 I148M. It is being investigated for the treatment of nonalcoholic steatohepatitis (NASH).
AMG 650 Hematology/Oncology Solid Tumors Small Molecule
DESCRIPTION AMG 650 is a small molecule KIF18A inhibitor. It is being investigated as a treatment for advanced solid tumors.
AMG 673 ® Hematology/Oncology Acute Myeloid Leukemia BiTE Molecule
DESCRIPTION AMG 673 is a half-life extended (HLE) anti-CD33 x anti-CD3 bispecific T cell engager (BiTE) molecule. It is being investigated for the treatment of acute myeloid leukemia (AML).
AMG 910 Gastric Cancer and ® Hematology/Oncology BiTE Molecule Gastroesophageal Junction Cancer
DESCRIPTION AMG 910 is a half-life extended (HLE) anti-CLDN18.2 x anti-CD3 bispecific T cell engager (BiTE) molecule. It is being investigated for the treatment of gastric and gastroesophageal junction cancer.
AMG 994 Hematology/Oncology Solid Tumors Bifunctional Fusion Protein
DESCRIPTION AMG 994 is a bispecific antibody. It is being investigated for the treatment of non-small cell lung cancer, mesothelioma, pancreatic cancer and ovarian cancer.
*Modalities in use across pipeline and marketed products. Modality refers to the structural template of a therapeutic agent.
This pipeline presents a selection of the Company’s product candidates and is designed to demonstrate the range of the Company’s commitment to patients in pursuing therapies to treat serious illnesses. We present a selection of these product candidates in our periodic reports based on their importance to the Company and our Annual Report on Form 10-K also includes an annual summary of activity for those Phase 3 product candidates selected for inclusion in our periodic filings. Unless otherwise noted, we are providing this information as of August 3, 2021 and expressly disclaim any duty to update any of the provided information. Amgen's product pipeline will change over time as molecules move through the drug development process, including progressing through clinical phases to licensure and market, returning to strategic partners, being outlicensed, or failing in clinical trials to demonstrate efficacy, safety or to deliver a commercially viable product, due to the nature of the development process. This description contains forward-looking statements that involve significant risks and uncertainties, including those discussed in Amgen's most recent Form 10-K and in Amgen's periodic reports on Form 10-Q and Form 8-K, and actual results may vary materially. Amgen is providing this information as of the date above and does not undertake any obligation to update any forward-looking statements contained in this table as a result of new information, future events or otherwise.
© 2021 Amgen Inc. All rights reserved. PAGE 11